8
|
Heggermont WA, Papageorgiou AP, Quaegebeur A, Deckx S, Carai P, Verhesen W, Eelen G, Schoors S, van Leeuwen R, Alekseev S, Elzenaar I, Vinckier S, Pokreisz P, Walravens AS, Gijsbers R, Van Den Haute C, Nickel A, Schroen B, van Bilsen M, Janssens S, Maack C, Pinto Y, Carmeliet P, Heymans S. Inhibition of MicroRNA-146a and Overexpression of Its Target Dihydrolipoyl Succinyltransferase Protect Against Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction. Circulation 2017; 136:747-761. [PMID: 28611091 DOI: 10.1161/circulationaha.116.024171] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2016] [Accepted: 05/10/2017] [Indexed: 11/16/2022]
Abstract
BACKGROUND Cardiovascular diseases remain the predominant cause of death worldwide, with the prevalence of heart failure continuing to increase. Despite increased knowledge of the metabolic alterations that occur in heart failure, novel therapies to treat the observed metabolic disturbances are still lacking. METHODS Mice were subjected to pressure overload by means of angiotensin-II infusion or transversal aortic constriction. MicroRNA-146a was either genetically or pharmacologically knocked out or genetically overexpressed in cardiomyocytes. Furthermore, overexpression of dihydrolipoyl succinyltransferase (DLST) in the murine heart was performed by means of an adeno-associated virus. RESULTS MicroRNA-146a was upregulated in whole heart tissue in multiple murine pressure overload models. Also, microRNA-146a levels were moderately increased in left ventricular biopsies of patients with aortic stenosis. Overexpression of microRNA-146a in cardiomyocytes provoked cardiac hypertrophy and left ventricular dysfunction in vivo, whereas genetic knockdown or pharmacological blockade of microRNA-146a blunted the hypertrophic response and attenuated cardiac dysfunction in vivo. Mechanistically, microRNA-146a reduced its target DLST-the E2 subcomponent of the α-ketoglutarate dehydrogenase complex, a rate-controlling tricarboxylic acid cycle enzyme. DLST protein levels significantly decreased on pressure overload in wild-type mice, paralleling a decreased oxidative metabolism, whereas DLST protein levels and hence oxidative metabolism were partially maintained in microRNA-146a knockout mice. Moreover, overexpression of DLST in wild-type mice protected against cardiac hypertrophy and dysfunction in vivo. CONCLUSIONS Altogether we show that the microRNA-146a and its target DLST are important metabolic players in left ventricular dysfunction.
Collapse
Affiliation(s)
- Ward A Heggermont
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Anna-Pia Papageorgiou
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Annelies Quaegebeur
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Sophie Deckx
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Paolo Carai
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Wouter Verhesen
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Guy Eelen
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Sandra Schoors
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Rick van Leeuwen
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Sergey Alekseev
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Ies Elzenaar
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Stefan Vinckier
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Peter Pokreisz
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Ann-Sophie Walravens
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Rik Gijsbers
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Chris Van Den Haute
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Alexander Nickel
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Blanche Schroen
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Marc van Bilsen
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Stefan Janssens
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Christoph Maack
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Yigal Pinto
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Peter Carmeliet
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.)
| | - Stephane Heymans
- From Center for Molecular and Vascular Research, Leuven, Belgium (W.H., A.P., S.D., Pa.C., P.P., A.S.W., S.J., S.H.); Center for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands (W.H., A.P., S.D., Pa.C., W.V., R.v.L., B.S., M.v.B., S.H.); Cardiovascular Research Center, OLV Hospital, Aalst, Belgium (W.H.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Leuven, Belgium (A.Q., G.E., S.S., S.V., Pe.C.); Amsterdam Medical Center, Amsterdam University, The Netherlands (S.A., I.E., Y.P.); Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences (R.G., C.V.D.H.), Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences (R.G., C.V.D.H.), Leuven Viral Vector Core, Belgium (R.G., C.V.D.H.); and Klinik für Innere Medezin III, Universitätsklinikum des Saarlandes, Homburg, Germany (A.N., C.M.).
| |
Collapse
|